Intracavitary bacillus calmette-guerin in the treatment of superficial bladder tumors
Bibliographic record
Abstract
No AccessJournal of Urology1 Feb 2002Intracavitary bacillus calmette-guerin in the treatment of superficial bladder tumors A. Morales, D. Eidinger, and A.W. Bruce A. MoralesA. Morales Department of Urology, Queen's University, Kingston, Ontario, Canada Department of Microbiology and Immunology, Queen's University, Kingston, Ontario, Canada , D. EidingerD. Eidinger Department of Urology, Queen's University, Kingston, Ontario, Canada Department of Microbiology and Immunology, Queen's University, Kingston, Ontario, Canada , and A.W. BruceA.W. Bruce Department of Urology, Queen's University, Kingston, Ontario, Canada Department of Microbiology and Immunology, Queen's University, Kingston, Ontario, Canada View All Author Informationhttps://doi.org/10.1016/S0022-5347(02)80294-4AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Patients with recurrent superficial bladder tumors have been treated by vesical and intradermal administration of Bacillus Calmette-Guerin. The pattern of recurrence in 9 patients has been altered favorably. Although the findings are still preliminary they appear to hold promise of a new therapeutic approach to the treatment of a group of neoplasms for which effective therapy is still lacking. References 1. : Thiotepa bladder instillations: therapy and prophylaxis for superficial bladder tumors. J. Urol.1969; 101: 711. Google Scholar 2. : The management of superficial bladder tumors with intravesical epodyl. Brit. J. Urol.1973; 45: 84. Google Scholar 3. : Treatment of multiple superficial papillary tumors of the bladder by intracavitary yttrium-90. J. Urol.1975; 113: 480. Link, Google Scholar 4. : Immune response to urinary bladder tumours in man. Int. J. Cancer1970; 5: 39. Google Scholar 5. : Correlation among host immunocompetence and tumor stage, tumor grade and vascular permeation in transitional carcinoma. J. Urol.1973; 110: 526. Link, Google Scholar 6. : Immunotherapy of guinea pig cancer with BCG. Cancer1974; 34: 1532. Google Scholar 7. : Surface markers on human T and B lymphocytes. I. A large population of lymphocyte forming nonimmune rosettes with sheep red blood cells. J. Exp. Med.1973; 136: 207. Google Scholar 8. : Increased cytolytic activity of a subcellular fraction from mouse liver after B.C.G. injection. Lancet1973; 2: 1476. Google Scholar 9. : BCG stimulation of immune responsiveness in patients with malignant melanoma. Cancer1973; 32: 321. Google Scholar 10. : Results of administering B.C.G. to patients with melanoma. Lancet1974; 2: 1096. Google Scholar 11. : Chemoimmunotherapy for cancer of the head and neck. Amer. J. Surg.1973; 126: 507. Google Scholar 12. : Bacillus Calmette-Guerin in the treatment of adenocarcinoma of the kidney. J. Urol.1976; 115: 37. Google Scholar 13. : The effects of BCG on the dog bladder. Invest. Urol.1975; 12: 423. Google Scholar 14. : Histopathology of Mycobacterium bovis (BCG)-mediated tumor regression. Nat. Cancer Inst. Monogr.1972; 35: 345. Google Scholar 15. : Cell-mediated immunity to human tumors. Abrogation by serum factors and nonspecific effects of oral BCG therapy. Arch. Surg.1973; 107: 261. Google Scholar 16. : Immune reactivity in renal cancer a sequential study. J. Urol.1976; 115: 510. Link, Google Scholar 17. : Peripheral lymphocyte counts in breast carcinoma. An index of immune competence. Cancer1974; 34: 2014. Google Scholar © 2002 by American Urological Association, IncFiguresReferencesRelatedDetailsCited byDeb A, Wilson S, Rove K, Kumar B, Koul S, Lim D, Meacham R and Koul H (2011) Potentiation of Mitomycin C Tumoricidal Activity for Transitional Cell Carcinoma by Histone Deacetylase Inhibitors In Vitro [RETRACTED]Journal of Urology, VOL. 186, NO. 6, (2426-2433), Online publication date: 1-Dec-2011.DOVEDI S, KIRBY J, ATKINS H, DAVIES B and KELLY J (2018) CYCLOOXYGENASE-2 INHIBITION: A POTENTIAL MECHANISM FOR INCREASING THE EFFICACY OF BACILLUS CALMETTE-GUERIN IMMUNOTHERAPY FOR BLADDER CANCERJournal of Urology, VOL. 174, NO. 1, (332-337), Online publication date: 1-Jul-2005. Volume 167Issue 2 Part 2February 2002Page: 891-894 Advertisement Copyright & Permissions© 2002 by American Urological Association, IncMetricsAuthor Information A. Morales Department of Urology, Queen's University, Kingston, Ontario, Canada Department of Microbiology and Immunology, Queen's University, Kingston, Ontario, Canada Current address: Laboratory of Immunodiagnosis, Building 8, Room 118, National Institutes of Health, Bethesda, Maryland 20014. More articles by this author D. Eidinger Department of Urology, Queen's University, Kingston, Ontario, Canada Department of Microbiology and Immunology, Queen's University, Kingston, Ontario, Canada More articles by this author A.W. Bruce Department of Urology, Queen's University, Kingston, Ontario, Canada Department of Microbiology and Immunology, Queen's University, Kingston, Ontario, Canada More articles by this author Expand All Advertisement PDF downloadLoading ...
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame distilled prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.
Codex and Gemma teacher scores by category
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.000 | 0.000 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.000 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.000 |
| Insufficient payload (model declined to judge) | 0.001 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one teacher head, not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".